Literature DB >> 15665641

Nigerian HIV type 2 subtype A and B from heterotypic HIV type 1 and HIV type 2 or monotypic HIV type 2 infections.

Clement Zeh1, Danuta Pieniazek, Simon M Agwale, Kenneth E Robbins, Lillian Odama, N Sani-Gwarzo, Michael S Gboun, Uford S Inyang, Thomas M Folks, Charles Wambebe, Marcia L Kalish.   

Abstract

The presence of HIV-2 in Nigeria has been confirmed serologically, but not genetically. To determine the frequency of HIV-2 infections and the dynamics between HIV-1 and HIV-2 in 35 of 36 Nigerian states, 420 blood samples were collected in 1999. Antibodies to HIV-1 and HIV-2 were detected by EIA and seroreactivity was confirmed with the INNO-LIA HIV Line Assay. The frequency of HIV-2 was 4.3% (18 of 420), with 3.8% (16 of 420) HIV-1 and HIV-2 (HIV-1/2) heterotypic and 0.5% (2 of 420) HIV-2 homotypic infections. The presence of HIV-2 subtype B in the two monotypic HIV-2 infections and subtype A in 11 (68.8%) of 16 HIV-1/2 dually seropositive samples was established by sequencing and phylogenetic analysis. HIV-2 subtype B viruses were not found in any of the HIV-1/2 dual infections, and HIV-2 subtype A strains were not identified in either of the two monotypic HIV-2 infections. Since our sample size was small and represented only convenience samples, larger randomized studies will be needed to better understand the dynamics of infection between HIV-1 and different HIV-2 subtypes and to determine whether significant biological differences exist among the HIV- 2 subtypes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15665641     DOI: 10.1089/aid.2005.21.17

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

1.  HIV diversity, molecular epidemiology, and the role of recombination.

Authors:  Gustavo H Kijak; Francine E McCutchan
Journal:  Curr Infect Dis Rep       Date:  2005-11       Impact factor: 3.725

2.  Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A.

Authors:  Nuno R Faria; Ioannis Hodges-Mameletzis; Joana C Silva; Berta Rodés; Smit Erasmus; Stefania Paolucci; Jean Ruelle; Danuta Pieniazek; Nuno Taveira; Ana Treviño; Maria F Gonçalves; Sabelle Jallow; Li Xu; Ricardo J Camacho; Vincent Soriano; Patrick Goubau; João D de Sousa; Anne-Mieke Vandamme; Marc A Suchard; Philippe Lemey
Journal:  J Gen Virol       Date:  2011-12-21       Impact factor: 3.891

3.  Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Taï Forest, Côte d'Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2.

Authors:  Mario L Santiago; Friederike Range; Brandon F Keele; Yingying Li; Elizabeth Bailes; Frederic Bibollet-Ruche; Cecile Fruteau; Ronald Noë; Martine Peeters; John F Y Brookfield; George M Shaw; Paul M Sharp; Beatrice H Hahn
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  HIV infection awareness and willingness to participate in future HIV vaccine trials across different risk groups in Abuja, Nigeria.

Authors:  Gambo Aliyu; Mukhtar Mohammad; Ahmed Saidu; Prosanta Mondal; Man Charurat; Alash'le Abimiku; Abdulsalami Nasidi; William Blattner
Journal:  AIDS Care       Date:  2010-10

5.  Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2.

Authors:  Morgan E Meissner; Nora A Willkomm; Jamie Lucas; William G Arndt; Sarah F Aitken; Emily J Julik; Sunanda Baliga; Louis M Mansky
Journal:  J Mol Biol       Date:  2021-11-10       Impact factor: 5.469

6.  Evaluation of HIV infection in febrile patients visiting health centers in Lagos, Nigeria.

Authors:  Ololade O Akinnusi; Adebayo J Bello; Isaac A Adeleye; Jerry John Nutor
Journal:  BMC Res Notes       Date:  2022-02-19

7.  Conservation of Nef function across highly diverse lineages of SIVsmm.

Authors:  Jan Schmökel; Hui Li; Elizabeth Bailes; Michael Schindler; Guido Silvestri; Beatrice H Hahn; Cristian Apetrei; Frank Kirchhoff
Journal:  Retrovirology       Date:  2009-04-09       Impact factor: 4.602

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.